Physician profile
Robert T Kizer
NPI 1770500514
$4,701.03
in general payments reported to CMS, 2019-2025
26 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $761 · 2020: $326 · 2021: $572 · 2022: $752 · 2023: $801 · 2024: $812 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,181 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,180.78 |
| Education | $109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,364.02 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Abbvie INC. | $975.93 | 2019-2025 | |
| Gilead Sciences, INC. | $446.16 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $441.52 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.97 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $193.44 | 2019-2025 | |
| Genzyme Corporation | $184.10 | 2022-2025 | |
| Qol Medical, LLC | $124.77 | 2019-2021 | |
| Celgene Corporation | $108.26 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $97.05 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $69.57 | 2023-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $66.17 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.35 | 2024 | Cyltezo |
| Celltrion USA INC. | $37.25 | 2025 | Vegzelma |
| Ardelyx, INC. | $29.64 | 2024 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $24.55 | 2025 | Rezdiffra |
| Kci USA, INC. | $19.16 | 2021 | |
| Fresenius Kabi USA, LLC | $19.12 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $17.72 | 2022 | |
| Sandoz INC. | $17.24 | 2024 | Hyrimoz |
| Ironwood Pharmaceuticals, INC | $17.16 | 2019 | |
| Welch Allyn | $16.90 | 2021 | |
| Ucb, INC. | $15.71 | 2019 | |
| Allergan, INC. | $12.40 | 2019 | |
| Braintree Laboratories, INC. | $11.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kizer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.